Estabrook Capital Management’s AstraZeneca AZN Stock Holding History

Estabrook Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.9K	Hold	237	–	–	0.01%	208
2026 Q1	$46.7K	Sell	237 -1	-0.4%	-$193	0.01%	198
2025 Q4	$43.7K	Hold	238	–	–	0.01%	196
2025 Q3	$36.4K	Hold	238	–	–	0.01%	209
2025 Q2	$33.2K	Hold	238	–	–	0.01%	207
2025 Q1	$34.9K	Hold	238	–	–	0.01%	201
2024 Q4	$31.1K	Hold	238	–	–	﹤0.01%	213
2024 Q3	$37K	Hold	238	–	–	0.01%	213
2024 Q2	$37K	Hold	238	–	–	0.01%	213
2024 Q1	$32.2K	Hold	238	–	–	0.01%	222
2023 Q4	$32K	Hold	238	–	–	0.01%	222
2023 Q3	$32.2K	Hold	238	–	–	0.01%	226
2023 Q2	$34K	Hold	238	–	–	0.01%	232
2023 Q1	$33K	Hold	238	–	–	0.01%	239
2022 Q4	$32.2K	Hold	238	–	–	0.01%	239
2022 Q3	$26K	Hold	238	–	–	﹤0.01%	249
2022 Q2	$31.4K	Hold	238	–	–	0.01%	248
2022 Q1	$31.5K	Hold	238	–	–	﹤0.01%	253
2021 Q4	$27.7K	Buy	+238	New	+$28K	﹤0.01%	270
2018 Q4	–	Sell	-85	Closed	-$6.73K	–	340
2018 Q3	$6.73K	Buy	+85	New	+$6.43K	﹤0.01%	313

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Estabrook Capital Management's AZN Position: Q2 2026 in Review

Estabrook Capital Management held its AstraZeneca (AZN) position steady in Q2 2026 at 237 shares worth $44.9K. The position accounts for 0.01% of the portfolio, ranked #208.

Estabrook Capital Management first reported a position in AZN in Q3 2018 and has held it in 20 quarters since. The position peaked at $46.7K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Estabrook Capital Management held 237 shares of AstraZeneca worth $44.9K as of Q2 2026.
Estabrook Capital Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Estabrook Capital Management's portfolio in Q2 2026, its #208 holding.
Estabrook Capital Management first reported a position in AstraZeneca in Q3 2018 and has held it in 20 quarters since.
Estabrook Capital Management's AstraZeneca position peaked at $46.7K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Estabrook Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.